Aarti Drugs filed its FY26 Sustainability Report.

The company temporarily stopped a chlorosulfonation process at its T-150 unit following an HCl gas leak, per MPCB directives.

It reported a Turnover of ₹2,260.39 Cr, boosting R&D/Capex for environmental and social improvements, including ZLD at 10 API facilities.